Phase I Study of Escalating Doses of IM-862 [oglufanide] in Patients With Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2012
At a glance
- Drugs Oglufanide (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacodynamics
- 22 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Sep 2005 New trial record.